MARKET

TRVN

TRVN

Trevena
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.9640
-0.0010
-0.10%
Closed 16:00 10/23 EDT
OPEN
0.9571
PREV CLOSE
0.9650
HIGH
0.9853
LOW
0.9500
VOLUME
168.39K
TURNOVER
--
52 WEEK HIGH
2.000
52 WEEK LOW
0.3823
MARKET CAP
89.23M
P/E (TTM)
-3.6557
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of TRVN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

TRVN News

  • Trevena Announces Presentations at the American Society of Anesthesiologists 2019 Annual Meeting
  • GlobeNewswire.2d ago
  • Easy Come, Easy Go: How Trevena (NASDAQ:TRVN) Shareholders Got Unlucky And Saw 84% Of Their Cash Evaporate
  • Simply Wall St..5d ago
  • Trevena to Present at the 2019 Cantor Global Healthcare Conference
  • GlobeNewswire.09/27 12:00
  • Johnson Fistel, LLP Announces Investigations of Trevena, Inc. and IVERIC bio, Inc.; Long Term Investors Encouraged to Contact the Firm
  • PR Newswire.09/20 13:46

More

Industry

Biotechnology & Medical Research
+0.09%
Pharmaceuticals & Medical Research
-0.25%

Hot Stocks

Name
Price
%Change

About TRVN

Trevena Inc. is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers. It is also developing TRV250, a G protein biased ligand targeting the o-receptor, as a compound with a non-narcotic mechanism for the treatment of migraine. TRV250 also may have utility in a range of other central nervous system (CNS) indications. It is focused on commencing a Phase I study of TRV250 in the United Kingdom. Its ABLE product platform is a collection of biological information, in vitro assays, know-how and expertise that it uses to identify unique G protein coupled receptors (GPCR)-targeted biased ligands with various pharmaceutical properties.
More

Webull offers Trevena Inc (TRVN) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.